Table 3.

Marburg countermeasures – treatment with antibodies.

Therapy	Manufacturer or source/contact	Description	NHP studies	Human use (INDs, case reports, phase 1 or 2)	Phase 3/RCTs	Regulatory approvals	Notes/special populations
Polyclonal concentrated IgG		Concentrated IgG derived from previously vaccinated NHP survivors from Marburg challenge	100% protection (6 NHPs) with three doses starting 15–30 min or 48 h after infection
Monoclonal antibodies
MR 191-N	Mapp Biopharmaceuticals, San Diego, CA, and Kentucky Bioprocessing	Human monoclonal antibody made in Nicotiana tobacco plants binds the receptor binding site of Marburg GP	12/13 and 3/3 NHPs survived with treatment at D4/D7 or D5/D8 post infection	Used as an emergency IND for a U.S. lab exposure. Details not public